TRAIL   Click here for help

GtoPdb Ligand ID: 5065

Synonyms: Apo-2 ligand (Apo-2L)
Comment: TRAIL is a cytokine of the tumor necrosis factor (TNF) ligand family. TRAIL binds to several TNF family receptors, activating MAPK8/JNK, caspase 8, and caspase 3. Its interaction with death receptors on tumor cells triggers apoptosis. Binding to decoy receptors may neutralise TRAIL activity. Because TRAIL exhibits much stronger apoptotic activity than other TNF family members, kills tumor cells more effectively than normal cells, and presents less risk of inducing an inflammatory repsonse following systemic administration, use of TRAIL as an anti-cancer therapeutic has been widely examined. Huang et al. (2017) [2] describe the development and potent anti-tumor activity of a TRAIL fusion protein nanoparticle formulation in a xenograft model [1]. To date, no pharmaceutical agents targeting TRAIL or its receptors in cancer have been approved.
Species: Human
Click here for help
1. Cao L, Du P, Jiang SH, Jin GH, Huang QL, Hua ZC. (2008)
Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature.
Mol Cancer Ther, 7 (4): 851-61. [PMID:18413798]
2. Huang K, Duan N, Zhang C, Mo R, Hua Z. (2017)
Improved antitumor activity of TRAIL fusion protein via formation of self-assembling nanoparticle.
Sci Rep, 7: 41904. [PMID:28225020]
3. Zhou T, Ichikawa K, Kimberley RP, Koopman WJ. (2001)
An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof.
Patent number: WO2001083560. Assignee: Uab Research Foundation. Priority date: 02/05/2000. Publication date: 08/11/2001.